Myeloproliferative sarcoma virus |
Infection of wild-type virus |
BM and spleen fibrosis |
42 |
TPO overexpression |
Transgenic (APOE promoter) |
Increased megakaryopoiesis but no overt myelofibrosis |
43 |
TPO overexpression |
Transgenic (IgH promoter) |
Increased megakaryopoiesis accompanied by elevated TGF-β and myelofibrosis |
44 |
TPO overexpression |
Retroviral transduction and transplantation |
BM and spleen fibrosis |
97 |
GATA-1low
|
Deletion of gene regulatory elements |
Aberrant megakaryopoiesis with gradual development of myelofibrosis |
57 |
OTT-MAL translocation |
Knock-in |
Requires retroviral introduction of a MPLW515L to develop myelofibrosis |
55 |
JAKT2875N mutation |
Retroviral transduction and transplantation |
Mixed characteristics of AMKL and MPN |
19 |
JAK2V617F mutation |
Transgenic |
Depending on promoter, phenotype can resemble PV or ET; mice develop myelofibrosis |
49 |
JAK2V617F mutation |
Retroviral transduction and transplantation |
Development of myelofibrosis was variable between mouse strains |
50 |
JAK2V617F mutation |
Retroviral transduction and transplantation |
Myelofibrosis accompanied by osteosclerosis |
51 |
JAK2V617F mutation |
Knock-in |
Splenomegaly with atypical MKs exhibiting emperipolesis; absence of fibrosis; resembles PV with evidence of thrombotic episodes |
47 |
JAK2V617F mutation |
Conditional knock-in |
Similar features with JAK2V617F knock-in model but fibrosis is present; resembles PV |
48 |
RBM6-CSF1R fusion protein |
Retroviral transduction and transplantation |
Variable phenotype; spleen reticulosis |
98 |
MPLW515L mutation |
Retroviral transduction and transplantation |
BM reticulosis; rapidly lethal |
53 |
MPLT487A mutation |
Retroviral transduction and transplantation |
Similar but less aggressive course to MPLW515L model |
54 |
Ts65Dn mouse strain |
Induced translocation resulting in segmental trisomy of distal chromosome 16 |
Myelofibrosis after the first year of life |
58 |
BACH1 |
Transgenic |
GATA-1 promoter drives expression; BACH1 mutation has not been reported in MPN |
99 |
NF-E2 overexpression |
Transgenic |
Abnormally clustered MKs; increased deposition of collagen and reticulin |
100 |